AFP
CLSD

Ausdal Financial Partners’s Clearside Biomedical CLSD Stock Holding History

Ausdal Financial Partners’s Portfolio CLSD Stock Details CLSD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-787
Closed -$94K – 317
2017
Q1 		$94K Buy
+787
New +$92.9K 0.04% 276

Other funds holding CLSD

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
HIM
Hillhouse Investment Management Grand Cayman, Cayman Islands $3.13B AUM 7.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Ausdal Financial Partners's CLSD Position: Q2 2017 in Review

Ausdal Financial Partners sold out of Clearside Biomedical (CLSD) in Q2 2017, closing a stake of 787 shares — an estimated $94K sold.

Ausdal Financial Partners first reported a position in CLSD in Q1 2017 and held it in 1 quarter. The position peaked at $94K in Q1 2017. 53 funds tracked by Wall St. Rank hold CLSD as of Q2 2017.

  • Ausdal Financial Partners reported no remaining Clearside Biomedical position as of Q2 2017 after selling out during the quarter.
  • Ausdal Financial Partners sold 787 Clearside Biomedical shares in Q2 2017, an estimated $94K.
  • Ausdal Financial Partners first reported a position in Clearside Biomedical in Q1 2017 and held it in 1 quarter.
  • Ausdal Financial Partners's Clearside Biomedical position peaked at $94K in Q1 2017.
  • 53 funds tracked by Wall St. Rank held Clearside Biomedical as of Q2 2017.

Based on Ausdal Financial Partners's 13F filing for Q2 2017, filed 11 Aug 2017.